Válek J, Jirkovská A, Grafnetter D
Institut klinické a experimentální medicíny, Praha.
Cas Lek Cesk. 1991 Feb 8;130(6):172-6.
To a group of 24 subjects with hypercholesterolaemia (hyperlipoproteinaemia type II) for a period of three months the non-absorbable resin Colestid was administered in order to reduce levels of atherogenic lipids and lipoproteins. The Colestid doses were graded from 5 g in the first month to 10-15 g during the third month. Reduction of cholesterol levels and the LDL fraction was significant already during the first month of treatment. The greatest reduction of LDL cholesterol was 25% and of total cholesterol 15%. A favourable effect was recorded also in HDL cholesterol which increased. The rise of triacylglycerols was not significant. Differences in the serum lipid response or their fractions did not depend on sex (15 women, 9 men), the clinical symptomatology (IHD) or family-history of atherosclerosis or concurrent administration of fibrates (Lipanthyl in 7 patients). In view of the small doses the symptomatology of side-effects was poor. Four patients, however, did not complete three months of treatment. With regard to the economical aspect of therapy and the favourable effect of small doses the authors draw attention to this experience which can be used as a basis also when using combinations with other preparations of antihypercholesterolemic therapy in those patients where an adequate reduction of cholesterol and its LDL fraction is not achieved.
对一组24名高胆固醇血症(II型高脂蛋白血症)患者进行为期三个月的治疗,给予不可吸收树脂考来替泊,以降低致动脉粥样硬化脂质和脂蛋白水平。考来替泊剂量从第一个月的5克逐渐增加到第三个月的10 - 15克。治疗第一个月期间,胆固醇水平和低密度脂蛋白(LDL)组分就已显著降低。LDL胆固醇的最大降幅为25%,总胆固醇降幅为15%。高密度脂蛋白(HDL)胆固醇也有升高的有利效果。甘油三酯的升高不显著。血清脂质反应及其组分的差异不取决于性别(15名女性,9名男性)、临床症状(缺血性心脏病)、动脉粥样硬化家族史或是否同时服用贝特类药物(7名患者服用力平之)。鉴于剂量较小,副作用症状不明显。然而,有4名患者未完成三个月的治疗。考虑到治疗的经济方面以及小剂量的有利效果,作者提请注意这一经验,在那些胆固醇及其LDL组分未充分降低的患者中,当与其他抗高胆固醇血症治疗制剂联合使用时,这一经验也可作为依据。